JP4955392B2 - 血管内膜過増殖疾患の予防または治療剤 - Google Patents
血管内膜過増殖疾患の予防または治療剤 Download PDFInfo
- Publication number
- JP4955392B2 JP4955392B2 JP2006528726A JP2006528726A JP4955392B2 JP 4955392 B2 JP4955392 B2 JP 4955392B2 JP 2006528726 A JP2006528726 A JP 2006528726A JP 2006528726 A JP2006528726 A JP 2006528726A JP 4955392 B2 JP4955392 B2 JP 4955392B2
- Authority
- JP
- Japan
- Prior art keywords
- intimal
- mitiglinide
- pharmaceutical composition
- drugs
- coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(1)前記式(I)で表されるミチグリニド若しくはその薬理学的に許容される塩、またはそれらの水和物を有効成分として含有する、血管内膜過増殖に起因する疾患の予防及び治療用医薬組成物;
(2)血管内膜過増殖に起因する疾患が、冠動脈バイパス術または冠動脈インターベンションの術後再狭窄である、前記(1)記載の医薬組成物;
(3)前記式(I)で表されるミチグリニドのカルシウム塩またはその水和物を有効成分として含有する、前記(1)または(2)記載の医薬組成物;
(4)抗アレルギー薬、抗血小板薬、アンジオテンシン変換酵素阻害薬、アンジオテンシンII受容体拮抗薬、キマーゼ阻害薬及び細胞増殖抑制薬から選択される1種類以上の薬剤と組み合わせて用いられる、前記(1)〜(3)のいずれか記載の医薬組成物;等に関するものである。
日本白色ウサギ(体重2.0〜3.3kg)にアロキサン50mg/kgを投与して作製した糖尿病モデル動物を、アロキサン投与翌日から試験終了前日までの6週間、0.5%カルボキシメチルセルロース溶液に懸濁したミチグリニドカルシウム水和物3mg/kgを1日1回食前に反復経口投与するミチグリニド投与群(5例)と、0.5%カルボキシメチルセルロース溶液のみを同様に投与する対照群(4例)に分けた。アロキサン投与2週間後に右総頸動脈内皮をバルーンカテーテルにて擦過し、擦過後、狭窄が生じないよう注意しつつ血管切開部を縫合した。左総頸動脈は偽手術側(正常群)とした。血管内皮擦過施行4週間後に両側総頸動脈を摘出し、血管組織切片の内膜、中膜及び管腔面積を画像解析装置にて測定した。また、アロキサン投与2週間後(血管内皮擦過日)及び6週間後(血管摘出日)の空腹時血漿グルコース濃度を測定した。
Claims (3)
- ミチグリニド若しくはその薬理学的に許容される塩、またはそれらの水和物を有効成分として含有する、冠動脈バイパス術または冠動脈インターベンションの術後再狭窄の予防又は治療用医薬組成物。
- ミチグリニドのカルシウム塩またはその水和物を有効成分として含有する、請求項1記載の医薬組成物。
- 抗アレルギー薬、抗血小板薬、アンジオテンシン変換酵素阻害薬、アンジオテンシンII受容体拮抗薬、キマーゼ阻害薬及び細胞増殖抑制薬から選択される1種類以上の薬剤と組み合わせて用いられる、請求項1又は2記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006528726A JP4955392B2 (ja) | 2004-07-01 | 2005-06-29 | 血管内膜過増殖疾患の予防または治療剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004195421 | 2004-07-01 | ||
JP2004195421 | 2004-07-01 | ||
PCT/JP2005/011896 WO2006003907A1 (ja) | 2004-07-01 | 2005-06-29 | 血管内膜過増殖疾患の予防または治療剤 |
JP2006528726A JP4955392B2 (ja) | 2004-07-01 | 2005-06-29 | 血管内膜過増殖疾患の予防または治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006003907A1 JPWO2006003907A1 (ja) | 2008-04-17 |
JP4955392B2 true JP4955392B2 (ja) | 2012-06-20 |
Family
ID=35782715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006528726A Expired - Fee Related JP4955392B2 (ja) | 2004-07-01 | 2005-06-29 | 血管内膜過増殖疾患の予防または治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070254938A1 (ja) |
JP (1) | JP4955392B2 (ja) |
CA (1) | CA2571822A1 (ja) |
TW (1) | TW200607498A (ja) |
WO (1) | WO2006003907A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114246905A (zh) * | 2020-09-21 | 2022-03-29 | 山东新时代药业有限公司 | 一种中药组合物在制备防治冠心病pci术后再狭窄药物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002474A1 (ja) * | 2002-06-28 | 2004-01-08 | Kissei Pharmaceutical Co., Ltd. | 糖尿病性合併症の予防又は進展阻止用医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU654331B2 (en) * | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
US5441947A (en) * | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
AU6120298A (en) * | 1997-03-07 | 1998-09-22 | Takeda Chemical Industries Ltd. | 2-peperazinone-1-acetic acid derivatives and their use |
JPH10306092A (ja) * | 1997-03-07 | 1998-11-17 | Takeda Chem Ind Ltd | 2−ピペラジノン−1−酢酸誘導体及びその用途 |
PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
CA2490250A1 (en) * | 2002-06-28 | 2004-01-08 | Kissei Pharmaceutical Co., Ltd. | Drug composition for blood sugar control |
-
2005
- 2005-06-29 JP JP2006528726A patent/JP4955392B2/ja not_active Expired - Fee Related
- 2005-06-29 US US11/630,874 patent/US20070254938A1/en not_active Abandoned
- 2005-06-29 WO PCT/JP2005/011896 patent/WO2006003907A1/ja active Application Filing
- 2005-06-29 CA CA002571822A patent/CA2571822A1/en not_active Abandoned
- 2005-07-01 TW TW094122300A patent/TW200607498A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002474A1 (ja) * | 2002-06-28 | 2004-01-08 | Kissei Pharmaceutical Co., Ltd. | 糖尿病性合併症の予防又は進展阻止用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO2006003907A1 (ja) | 2006-01-12 |
US20070254938A1 (en) | 2007-11-01 |
CA2571822A1 (en) | 2006-01-12 |
TW200607498A (en) | 2006-03-01 |
JPWO2006003907A1 (ja) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050019366A1 (en) | Drug-coated stents and methods of use therefor | |
ES2600783T3 (es) | Régimen de dosificación de edoxabán | |
US20070202140A1 (en) | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery | |
TW200817000A (en) | New paediatric indications for direct thrombin inhibitors | |
US10220072B2 (en) | Mesalamine for the treatment of cancer | |
JP4955392B2 (ja) | 血管内膜過増殖疾患の予防または治療剤 | |
JP4783152B2 (ja) | 血管内膜肥厚抑制薬 | |
JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
WO2005039556A1 (ja) | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 | |
JP4843313B2 (ja) | 食道の運動障害を伴う疾患の予防または治療用医薬組成物 | |
AU2002305164B2 (en) | Method of inhibiting adhesion formation | |
JP4855073B2 (ja) | 併用医薬 | |
JP2532918B2 (ja) | グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤 | |
CN1914194B (zh) | 用于伴随旁路术的血管痉挛的治疗剂 | |
WO2003047591A1 (en) | Remedies for primary pulmonary hypertension | |
WO1998043626A1 (fr) | Medicaments s'opposant a la reconstriction | |
JP2015526493A (ja) | 冠動脈バイパス移植術を受けることが予定されている患者の非st上昇型急性冠症候群の治療において使用するためのオタミキサバン | |
WO2016204239A1 (ja) | TAFIa阻害剤とプラスミノーゲンアクチベータの組み合わせ | |
US20090239872A1 (en) | Treatment of mesothelioma | |
JP2005041801A (ja) | 細胞移植療法後の予後改善剤 | |
JPH08165239A (ja) | 抗動脈硬化剤 | |
JP2000191535A (ja) | 血管平滑筋細胞増殖に起因する疾患用薬 | |
JP2003104894A (ja) | 動脈瘤治療剤または予防剤 | |
JP2005206494A (ja) | 細胞移植療法後の予後改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080605 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110927 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120313 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4955392 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150323 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |